Morepen Laboratories
NSE:MOREPENBaddi, India· Est.
Indian‑based API and generic drug manufacturer with USFDA‑approved plants and a growing CDMO business.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
Indian‑based API and generic drug manufacturer with USFDA‑approved plants and a growing CDMO business.
CardiovascularRespiratoryAllergyAnti‑infectiveOTC Healthcare
Technology Platform
Proprietary chemical synthesis and polymorph engineering platforms enable high‑yield, cost‑effective API production, supported by USFDA‑approved facilities and extensive IP portfolio.
Opportunities
Expansion of CDMO services and new generic launches in high‑volume therapeutic segments can drive revenue growth.
Risk Factors
Regulatory compliance across multiple jurisdictions and pricing pressure from generic competition are key risk factors.
Competitive Landscape
Competes with Indian API leaders such as Sun Pharma, Cipla, and Dr. Reddy's; differentiation stems from USFDA‑approved plants, large‑scale capacity for specific APIs, and a strong patent portfolio.